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preferentially encoded nearby the activated HERVs in tumors and 39 transcriptionally regulated by the adjacent HERVs. Increased HERV and KZFP 40 expression in tumors was associated with better disease conditions. Many KZFPs 41 could suppress the progressive characteristics of cancer cells by downregulating 42 genes related to the cell cycle and cell-matrix adhesion. Our data suggest that 43 HERV activation in tumors drives the concerted expression of KZFP genes for 44 tumor suppression. 45 preferentially located in the vicinity of activated HERVs. Although KZFPs are 82 widely known as transcriptional silencers against TEs, including HERVs 28 , our 83 data highlight that the expression of KZFP genes is induced by the adjacent 84
HERVs in tumors, leading to global gene expression alterations and phenotypic 85 changes. 86 tumors and subsequently performed gene set enrichment analysis (GSEA) 29 123 based on the above correlation scores. We found that the genes showing a 124 correlation with HERVs were highly similar among distinct types of cancers (Figs. occur in cancer cells themselves. 137 138
Transcriptional activation of KZFP genes by surrounding HERVs 139
We hypothesized that derepressed HERVs near KZFP genes induce the 140 expression of these genes, leading to the synchronized expression of HERVs 141 and KZFP genes in tumors. It is known that KZFP genes form genomic clusters, 142 particularly on chromosome 19 in the human genome 31 . We found that the 143 expressed HERVs in tumors were preferentially present in these clusters of KZFP 144 genes ( Fig. 2A) . The expressed HERVs in tumors and those with transcriptional 145 regulatory signals (i.e., NFRs or enhancers defined by GeneHancer 32 ) were 146 highly enriched in the vicinity of transcriptional start sites (TSSs) of KZFP genes 147 ( Figs. 2B and S5A) . Several types of HERV LTRs, such as LTR70, LTR25, 148 LTR5B, and LTR5Hs, showed particularly strong enrichments around the TSSs 149 of KZFP genes (Fig. 2C) . 150 We next investigated the association between the transcriptional 151 upregulation of KZFP genes and the epigenetic activation of the adjacent HERVs 152 in tumors. The mean expression level of KZFP genes was associated with the 153 mean NFR activity of the expressed HERVs around those genes in tumors ( Fig.  154   2D) . Additionally, the mean expression level of KZFP genes in tumors was 155 negatively correlated with the mean DNA methylation level of the CpG sites that 156 are on or proximal (<1 kb) to the expressed HERVs around those genes (Fig. 157 enriched in the set of genes possibly regulated by HERVs (Fig. S5C) , supporting 164 the significance of HERVs in the transcriptional regulation of KZFP genes. Based 165 on these interactions, we constructed a network representing the regulation of 166 KZFP genes by HERVs ( Fig. 2E, middle) . We identified several "hub" HERV loci, 167 which are connected to many KZFP genes in the network and are likely to be 168 involved in the transcriptional regulation of these genes ( Fig. 2E, right) . 169
To experimentally address the significance of HERVs in the 170 transcriptional modulation of KZFP genes in cancer cells, we performed CRISPR-171
Cas9 excision of a hub HERV locus (HERV-enhancer1; Fig. 2E, right) in human 172 lung adenocarcinoma (LUAD) (A549) cells ( Figs. 2F and S6) . We particularly 173 selected this HERV locus because it displayed active histone marks in A549 cells 174 ( Fig. 2F) . We demonstrated that the homozygous excision of this HERV 175 decreased the expression of adjacent genes, including many KZFP genes ( Fig.  176   2G) . Since KZFPs are potent transcriptional suppressors 28 , it is possible that the 181 synchronized induction of many KZFPs in tumors would alter gene expression 182 globally and change the characteristics of tumors. We found that somatic 183 mutations accumulated particularly in the DNA-binding interfaces of KZFPs in 184 tumors ( Fig. 3A) , suggesting that the aberration of the DNA-binding activity of 185 KZFPs is associated with tumor progression. We therefore investigated the 186 associations of the expression of KZFPs and HERVs with the clinical outcomes 187 of cancer patients and found the following marked associations: in four (bladder 188 carcinoma (BLCA), head and neck squamous cell carcinoma (HNSC), kidney 189 renal papillary cell carcinoma (KIRP), and LUAD) out of twelve types of cancers, 190 patients with high expression levels of KZFPs and HERVs in the tumors tended 191 to show a better prognosis than those with low expression levels (Figs. 3B and 192 S7). Furthermore, we examined the association of the expression levels of 193
These results support the significance of HERVs in the transcriptional regulation 266 of these KZFP genes in cancer cells. 267
268
Discussion 269
In the present study, we found that the global activation of HERVs occurred in a 270 substantial fraction of tumors ( Figs. 1E and S1C) . Although the ultimate cause 271 of HERV activation in tumors is still unclear, the attenuation of the epigenetic 272 silencing of HERVs would be related to HERV activation (Figs. S1F and S1G). To control the quality of the RNA-Seq data used in the present study, we 339 checked the proportion of non-assigned RNA-Seq fragments (i.e., the fragments 340 that were uniquely mapped on the reference genome but not on HERVs or exons 341 of genes) in each sequence library. For this proportion, outlier libraries were 342 detected recursively using the Smirnov-Grubbs test (the threshold was set at 343 0.05). These outlier libraries were excluded from the downstream analyses. The 344
final RNA-Seq data used in this study are summarized in Data S4. 345
The expression count matrices of the RNA-Seq data were separately 346 prepared for the datasets of the respective types of cancers. In addition, the 347 expression matrix including all tumor data was also prepared. Furthermore, the 348 expression matrix, including the data from the tumors and corresponding normal 349 adjacent tissues, was also prepared for each type of cancer. Genes and HERVs 350 with low expression levels were removed from the expression matrix as follows. HERVs with low expression levels, and normalization of the expression data were 388 performed using the same procedures as those in the above section ("RNA-Seq 389 data analysis of the TCGA dataset"). 390 391
Dimension reduction analysis of HERV expression profiles using t-392 distributed stochastic neighbor embedding (t-SNE) 393
The expression matrix including all tumor data was used in this analysis. The 394 expression levels of the 1000 most highly expressed HERVs were used in the 395 analysis. t-SNE analysis was performed using the "Rtsne" R package. For the 396 analysis, the first 10 principle components of the HERV expression profiles were 397 used, and the parameter "perplexity" was set at 70. 398
399

ATAC-Seq data analysis 400
The ATAC-Seq data of tumors and normal adjacent tissues provided by TCGA 401 (TCGA-ATAC_PanCan_Log2Norm_Counts.rds) was downloaded from the GDC 402 website (https://gdc.cancer.gov/about-data/publications/ATACseq-AWG). This 403 file contains the normalized read count matrix comprising all ATAC-Seq samples 404 (n=796) and ATAC-Seq peaks (NFRs) (n=562,709) analyzed in the previous 405 study 4 . In the respective types of cancers, the upper ¼ of NFRs with respect to 406 the mean value were regarded as the NFRs that are active in the corresponding 407 cancer types. 408 counts in the randomized datasets was regarded as the random expectation 414 value. The fold enrichment was calculated by dividing the observed count by the 415 random expectation value. 416
417
DNA methylation data analysis 418
The DNA methylation data (produced by the methylation microarray 419 HumanMethylation450 (Illumina)) of tumors and normal tissue controls were 420 downloaded from the GDC data portal (http://portal.gdc.cancer.gov/) using the 421 GDC Data Transfer Tool (http://gdc.cancer.gov/access-data/gdc-data-transfer-422 tool/). These data describe the methylation level (beta value; proportion of 423 methylated CpGs at a CpG site) of each probe in the array. Probes overlapping 424 with single nucleotide polymorphisms (SNPs) with >0.05 minor allele frequency 425 were excluded from the analysis using the function "rmSNPandCH" implemented 426 in the "DMRcate" library 45 in R. The CpG sites that were on or proximal (<1 kb) 427
to HERVs were extracted using the "slop" and "intersect" functions in bedtools 44 . 428 DNA methylation data used in this study is summarized in Data S7. 429 430
Preparation of gene sets for enrichment analyses 431
As sources of gene sets, "GO biological process", "GO cellular component", 432
"MSigDB canonical pathway", and "InterPro" were used. The gene sets in these 433 sources were concatenated and used. "InterPro" is the collection of gene sets 434 according to protein families or domains and includes the gene set "KRAB", 435
representing the KZFP family genes. "GO biological process" and "GO cellular 436 component" were obtained from Gene Ontology (GO) consortium 437 (http://geneontology.org/; GO validation date: 08/30/2017); "canonical pathway" 438 was from MSigDB (http://software.broadinstitute.org/gsea/msigdb; version 6.1); 439 and "InterPro" was from BioMart on the Ensembl website 440 (https://www.ensembl.org; on 2/13/2018). 441
In addition, we defined the gene sets "HERVs" and "HERVs around KZFP To perform GSEA 29 , the R package "fgsea" 47 , a fast implementation of GSEA, 469 was used. The parameters of "number of permutations" and "minimum size of 470 gene set" were set at 10,000 and 50, respectively. In the analyses of Figs. 1F 471 and S4, the Spearman's correlations between the expression levels of respective 472 genes and the total expression level of HERVs were used as statistical scores. 473
In the analysis of Fig. S3 , the Spearman's correlations between the expression 474 levels of respective genes and the GSVA score of the KZFP genes were used. In 475 the analyses of Figs. 3D and S8B, Z scores in Cox proportional hazards 476 regression were used (the Z score is described in the "Survival analysis of the 477 cancer patients" section). In the analysis of Fig. S12A , Wald statistics of the 478 respective genes in the differential expression analysis were used (the Wald 479 statistic is described in the "Differential expression analysis" section). 480
Summarizing the results of GSEA and GO enrichment analysis by removing 482 redundant gene sets 483
Since the gene members of some gene sets highly overlapped with each other, 484 redundant gene sets were removed from the results of the enrichment analyses 485 as follows. Gene sets were ranked according to the score of interest (e.g., the 486 mean value of normalized enrichment score (NES)). If the gene members of a 487 certain gene set were highly overlapped with those of the upper-ranked gene sets, 488 the gene set was removed from the result. As a statistic of the overlap, the 489 Szymkiewicz-Simpson coefficient was used, and two gene sets were regarded 490 as highly overlapped if the coefficient was greater than 0.7. This gene set filtering 491 was applied to the analyses shown in Figs. 1F, S8B, S9B , S10, and S12A, which 492
show only the top-ranked gene sets. 493 494 GO enrichment analysis to identify gene sets that are preferentially present 495 in the vicinity of the expressed HERVs 496
Randomization-based GO enrichment analysis was performed as follows. Only 497 genes whose expression levels were detected in the TCGA tumor datasets were 498 used. Regions of interest were defined as the regions within 50 kb from the TSSs 499 of the gene members of a certain gene set. The genomic regions of HERVs were 500 randomized using the "shuffle" function of bedtools 44 , and subsequently, the 501 number of HERVs in the region of interest was counted. This process was 502 repeated 1,000 times, and the mean value of the counts in the randomized 503 datasets was regarded as the random expectation value. The fold enrichment 504 was calculated by dividing the observed count by the random expectation value. 505
Additionally, we calculated the fold enrichments of HERVs in the regions 506 within 10, 100, and 500 kb and 1 mb from the TSSs of the KZFP genes using the 507 same procedures as above. 508 509
Prediction of genes regulated by HERVs 510
The regulatory interactions between HERV loci and genes were predicted 511 according to the following information: co-expression between HERVs and genes, 512 positive correlations between HERV NFR activities and gene expression, 513 negative correlations between HERV DNA methylation and gene expression, and 514 pre-defined links between the regulatory sequences on HERVs and genes. The 
Association analysis of gene expression and cancer progression 572
Prostate adenocarcinoma (PRAD) tumors were excluded from the analysis since 573 information on cancer stage for most PRAD patients was not available. In the 574 analysis, cancer stage was regarded as an interval scale. For each type of cancer, 575 the association between the expression of each gene and the progression of the 576 cancer stage was evaluated by single linear regression. Similarly, the association 577 between the GSVA score of each gene set and the progression of cancer stage 578 for each type of cancer was evaluated using the same procedure. To evaluate 579 the pan-cancer association of the GSVA score of each gene set and the 580 progression of cancer stage, multiple linear regression analysis with adjustment 581 for the effects of cancer type was performed. 582 583
Analysis of a publicly available ChIP-Seq dataset of KZFPs 584
This analysis was based on a publicly available ChIP-Seq dataset of KZFPs in 585 HEK293T cells presented in a previous study (Imbeault et al. 33 ; GEO accession 586 #: GSE78099). Information on pre-defied ChIP-Seq peaks (GSE78099_RAW.tar) 587 was downloaded from the Gene Expression Omnibus (GEO) database 588 (https://www.ncbi.nlm.nih.gov/geo/). Since these ChIP-Seq peaks (referred to as 589 transcription factor binding sites; TFBSs) are for GRCh37/hg19, the genomic 590 coordinates of these TFBSs were converted to those in GRCh38/hg38 using 591 UCSC liftOver (http://hgdownload.soe.ucsc.edu/admin/exe/linux.x86_64/liftOver). 592
The option "minMatch" was set at 0.95. If multiple technical replicates of ChIP-593
Seq are available for one KZFP, the replicate files were merged using the 594 bedtools "merge" 44 with the options "-c 5 -o mean". KZFPs were removed from 595 the downstream analyses if the total number of TFBSs was less than 500. If 596 >10,000 TFBSs were available for one KZFP, only the high-scored 10,000 TFBSs 597 were used for the analyses. 598
To identify sets of genes that are preferentially targeted by a certain KZFP, 599 genomic region enrichment analysis (GREAT) 48 was performed as follows. Only 600 genes whose expression levels were detected in the TCGA tumor datasets were 601 used. Regions of interest were defined as the regions within 10 kb from the TSSs 602 of the gene members of a certain gene set. Regions of background were defined 603 as the regions within 10 kb from the TSSs of genes belonging to any of the gene 604 sets. The lengths of the regions of interest and regions of background were 605 calculated and referred to as Li and Lb, respectively. In the regions of interest and 606 regions of background, the numbers of TFBSs were counted (referred to as 607 counts of interest (Ci) and counts of background (Cb), respectively). The fold 608 enrichment value was calculated by dividing Ci/Cb by Li/Lb, and the statistical 609 significance was evaluated using a binomial test. 610 611 Differential expression analysis 612 Differential expression analysis was performed using DESeq2 (version 1.18.1) 41 613 in R. Genes that were included in any of the gene sets prepared above were used. 614 A549/KZFP cells and empty vector-transduced cells was compared (Fig. 4E) . 615
Additionally, comparison was conducted between A549 cells in which HERV-616 enhancer1 were excised versus the non-target control cells (Fig. 2G) . Statistical 617 significance was evaluated by the Wald test with false discovery rate (FDR) 618 correction using the Benjamini-Hochberg (BH) method. 619 620
Scoring system of genes for predicting the targets of KZFPs critical for 621 cancer progression 622
The scheme is summarized in Fig. S13A . For each gene, the following scores 623 were defined. The TCGA expressional correlation score was defined as the 624 of KZFPs in the TCGA dataset (the median value among all cancer types was 626 used). The CCLE expressional correlation score was also defined using the same 627 procedure but on the CCLE dataset. The prognosis score was defined as the Z 628 score representing the association of each gene with the prognosis of cancer the cancer patients". The progression score was defined as the t-score 632
representing the association of each gene with cancer progression (the mean 633 value among BLCA, BRCA, KIRC, KIRP, LUAD, and thyroid carcinoma (THCA) 634 tumors was used). This t-score was described in the above section "Association 635 analysis of gene expression and cancer progression". The suppression score 636 was defined as the mean value of the Wald scores in the differential expression 637 analysis among the A549/KZFP cells. This Wald score was described in the 638 above section "RNA-Seq analysis of A549/KZFP cells". Regarding the TCGA 639 and CCLE correlation scores and suppression scores, the signs of the scores 640 were inverted. All scores were standardized as Z scores and subsequently 641 quantile-normalized. Genes were extracted if the minimum score was greater 642 than 0.5 and the median score was greater than 1. Of the extracted genes, genes 643 targeted by ≥10 KZFPs were further extracted and regarded as the target genes 644 of KZFPs critical for cancer progression. A gene was regarded as the target of a 645 certain KZFP if the KZFP bound to the regions within 10 kb from the TSSs of the 646 gene. In this analysis, only TSSs of "principal transcripts" (Principals 1-3) defined 647 by APPRIS 49 were used. If >1,000 genes were assigned to a certain KZFP as its 648 targets, only the top 1,000 genes having high-scored TFBSs were used. 649 650
Data visualization 651
All visualizations were performed in R. Graphs were plotted using the "ggplot2" 652 package or the pre-implemented function "plot" unless otherwise noted. 653
Heatmaps were drawn using the "ComplexHeatmap" package 50 . Networks were 654 plotted using the "igraph" package. Kaplan-Meier plots were drawn using the 655 "ggsurvplot" function in the "survminer" package. information is summarized in Data S11. The gRNA was cloned into a gRNA 795 expression plasmid, lentiGuide-Puro (Addgene #52963). A pair of gRNA 796 expression plasmids was co-transfected into the A549/Cas9 cells by 797 electroporation using the NEON Transfection System (ThermoFisher) (1200 V; 798 30 ms; 2 times pulse; 1.0 x 10 5 cells; and 500 ng of each plasmid). After 799 transfection, the cells were selected with 1 µg/ml puromycin for 3 days. After 800 selection, single cell clones were obtained through the limiting dilution method. 801
Of these candidate clones, the clones in which homozygous or heterozygous 802 excision of the target HERV occurred were screened using PCR (Fig. S6) 
